Skip to main content
SpringerLink
Log in

Does the degree of hypothalamic-pituitary-ovarian recovery after oral contraceptive pills affect outcomes of IVF/ICSI cycles receiving GnRH-antagonist adjuvant therapy in women over 35 years of age?

  • ASSISTED REPRODUCTION TECHNOLOGIES
  • Published:
Journal of Assisted Reproduction and Genetics Aims and scope Submit manuscript

Abstract

Purpose

To evaluate if the degree of recovery of serum gonadotropins after oral contraceptive pills (OCP) pretreatment has an impact on ovarian response in GnRH-antagonist IVF cycles in women of advanced maternal age.

Methods

In this retrospective cohort study, we included 98 women 35–42 years undergoing their first IVF cycle receiving gonadotropins and a fixed GnRH-antagonist adjuvant protocol. Data analysis was carried out according to changes in serum FSH, LH and estradiol (E2) levels (basal and post-OCP) divided in quartiles, and also according to absolute levels. The main outcomes were peak serum E2, number of mature oocytes retrieved, length of stimulation, and amount of gonadotropins used.

Results

By quartile analysis, patients with the highest levels of serum gonadotropins suppression and also patients with gonadotropin rebound needed larger amounts of LH during the treatment. On the other hand, women with absolute suppression of FSH/LH had increased length of stimulation.

Conclusions

The results of this study provide data that assist in clinical management. Gonadotropin serum levels after OCP treatment provide information for optimization of supplementation with LH in GnRH-antagonist cycles in women over age 35.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Acevedo B, Sanchez M, Gomez JL, Cuadros J, Ricciarelli E, Hernandez ER. Luteinizing hormone supplementation increases pregnancy rates in gonadotropin-releasing hormone antagonist donor cycles. Fertil Steril. 2004;82:343–7.

    Article  PubMed  CAS  Google Scholar 

  2. Al-Inany HG, Youssef MA, Aboulghar M, Broekmans F, Sterrenburg M, Smit J, Abou-Setta AM. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2011;CD001750.

  3. Arslan M, Bocca S, Mirkin S, Barroso G, Stadtmauer L, Oehninger S. Controlled ovarian hyperstimulation protocols for in vitro fertilization: two decades of experience after the birth of Elizabeth Carr. Fertil Steril. 2005;84:555–69.

    Article  PubMed  CAS  Google Scholar 

  4. Barroso G, Oehninger S, Monzo A, Kolm P, Gibbons WE, Muasher SJ. High FSH:LH ratio and low LH levels in basal cycle day 3: impact on follicular development and IVF outcome. J Assist Reprod Genet. 2001;18:499–505.

    Article  PubMed  CAS  Google Scholar 

  5. Bjercke S, Fedorcsak P, Abyholm T, Storeng R, Ertzeid G, Oldereid N, Omland A, Tanbo T. IVF/ICSI outcome and serum LH concentration on day 1 of ovarian stimulation with recombinant FSH under pituitary suppression. Hum Reprod. 2005;20:2441–7.

    Article  PubMed  CAS  Google Scholar 

  6. Cai QF, Wan F, Huang R, Zhang HW. Factors predicting the cumulative outcome of IVF/ICSI treatment: a multivariable analysis of 2450 patients. Hum Reprod. 2011;26:2532–40.

    Article  PubMed  CAS  Google Scholar 

  7. Cedrin-Durnerin I, Bstandig B, Parneix I, Bied-Damon V, Avril C, Decanter C, Hugues JN. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre-treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Hum Reprod. 2007;22:109–16.

    Article  PubMed  CAS  Google Scholar 

  8. Centers for Disease Control and Prevention. 2009 Assisted Reproductive Technology and Success Rates. National Summary and Fertility Clinic Reports 2007.

  9. Devroey P, Aboulghar M, Garcia-Velasco J, Griesinger G, Humaidan P, Kolibianakis E, Ledger W, Tomas C, Fauser BC. Improving the patient’s experience of IVF/ICSI: a proposal for an ovarian stimulation protocol with GnRH antagonist co-treatment. Hum Reprod. 2009;24:764–74.

    Article  PubMed  CAS  Google Scholar 

  10. Dowling-Lacey D, Jones E, Mayer J, Bocca S, Stadtmauer L, Oehninger S. Elective transfer of two embryos: reduction of multiple gestations while maintaining high pregnancy rates. J Assist Reprod Genet. 2007;24:11–5.

    Article  PubMed  Google Scholar 

  11. Gonen Y, Jacobson W, Casper RF. Gonadotropin suppression with oral contraceptives before in vitro fertilization. Fertil Steril. 1990;53:282–7.

    PubMed  CAS  Google Scholar 

  12. Griesinger G, Shapiro DB, Kolibianakis EM, Witjes H, Mannaerts BM. No association between endogenous LH and pregnancy in a GnRH antagonist protocol: part II, recombinant FSH. Reprod Biomed Online. 2011;23:457–65.

    Article  PubMed  CAS  Google Scholar 

  13. Huirne JA, Homburg R, Lambalk CB. Are GnRH antagonists comparable to agonists for use in IVF? Hum Reprod. 2007;22:2805–13.

    Article  PubMed  CAS  Google Scholar 

  14. Kim CH, Jeon GH, Cheon YP, Jeon I, Kim SH, Chae HD, Kang BM. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low-dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertil Steril. 2009;92:1758–60.

    Article  PubMed  Google Scholar 

  15. Klein NA, Battaglia DE, Fujimoto VY, Davis GS, Bremner WJ, Soules MR. Reproductive aging: accelerated ovarian follicular development associated with a monotropic follicle-stimulating hormone rise in normal older women. J Clin Endocrinol Metab. 1996;81:1038–45.

    Article  PubMed  CAS  Google Scholar 

  16. Kolibianakis EM, Papanikolaou EG, Camus M, Tournaye H, Van Steirteghem AC, Devroey P. Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Hum Reprod. 2006;21:352–7.

    Article  PubMed  CAS  Google Scholar 

  17. Kolibianakis EM, Venetis CA, Kalogeropoulou L, Papanikolaou E, Tarlatzis BC. Fixed versus flexible gonadotropin-releasing hormone antagonist administration in in vitro fertilization: a randomized controlled trial. Fertil Steril. 2011;95:558–62.

    Article  PubMed  CAS  Google Scholar 

  18. Kolibianakis EM, Zikopoulos K, Schiettecatte J, Smitz J, Tournaye H, Camus M, Van Steirteghem AC, Devroey P. Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF. Hum Reprod. 2004;19:2490–6.

    Article  PubMed  CAS  Google Scholar 

  19. Mahutte NG, Arici A. Role of gonadotropin-releasing hormone antagonists in poor responders. Fertil Steril. 2007;87:241–9.

    Article  PubMed  CAS  Google Scholar 

  20. Meldrum DR, Schoolcraft W. Microdose flare versus antagonist for poor responders. Fertil Steril. 2010;93:e35. author reply e36.

    Article  PubMed  Google Scholar 

  21. Meldrum DR, Scott Jr RT, Levy MJ, Alper MM, Noyes N. Oral contraceptive pretreatment in women undergoing controlled ovarian stimulation in ganirelix acetate cycles may, for a subset of patients, be associated with low serum luteinizing hormone levels, reduced ovarian response to gonadotropins, and early pregnancy loss. Fertil Steril. 2009;91:1963–5.

    Article  PubMed  CAS  Google Scholar 

  22. Mochtar MH, Van der V, Ziech M, van Wely M. Recombinant Luteinizing Hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database Syst Rev. 2007;CD005070.

  23. Murphy MF, Campbell MJ, Bone M. Is there an increased risk of twinning after discontinuation of the oral contraceptive pill? J Epidemiol Commun Health. 1989;43:275–9.

    Article  CAS  Google Scholar 

  24. Neal-Perry G, Nejat E, Dicken C. The neuroendocrine physiology of female reproductive aging: An update. Maturitas. 2010;67:34–8.

    Article  PubMed  CAS  Google Scholar 

  25. Oehninger S. Ovulation induction in IVF. Minerva Ginecol. 2011;63:137–56.

    PubMed  CAS  Google Scholar 

  26. Pandian Z, McTavish AR, Aucott L, Hamilton MP, Bhattacharya S. Interventions for ‘poor responders’ to controlled ovarian hyper stimulation (COH) in in-vitro fertilisation (IVF). Cochrane Database Syst Rev. 2010;CD004379.

  27. Rombauts L, Healy D, Norman RJ. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist-treated patients. Hum Reprod. 2006;21:95–103.

    Article  PubMed  CAS  Google Scholar 

  28. Scott RT, Toner JP, Muasher SJ, Oehninger S, Robinson S, Rosenwaks Z. Follicle-stimulating hormone levels on cycle day 3 are predictive of in vitro fertilization outcome. Fertil Steril. 1989;51:651–4.

    PubMed  CAS  Google Scholar 

  29. Smulders B, van Oirschot SM, Farquhar C, Rombauts L, Kremer JA. Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques. Cochrane Database Syst Rev. 2010;CD006109.

  30. The European Recombinant Human LH Study Group. Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. J Clin Endocrinol Metab. 1998;83(5):1507–14.

    Article  Google Scholar 

  31. van Heusden AM, Fauser BC. Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives. Contraception. 1999;59:237–43.

    Article  PubMed  Google Scholar 

  32. Veeck LL. Extracorporeal maturation: Norfolk, 1984. Ann N Y Acad Sci. 1985;442:357–67.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Eastern Virginia Medical School, The Jones Institute for Reproductive Medicine, 601 Colley Ave, Norfolk, VA, USA

    Carla Schmitz, Silvina Bocca, Laurel Stadtmauer & Sergio Oehninger

  2. Attending Gynecologist, Pompeia Hospital, Caxias do Sul, RS, Brazil

    Carla Schmitz

  3. Graduate Program in Public Health, Eastern Virginia Medical School, Norfolk, VA, USA

    Hind Beydoun

Authors
  1. Carla Schmitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Silvina Bocca
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hind Beydoun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Laurel Stadtmauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sergio Oehninger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sergio Oehninger.

Additional information

Capsule

Variable changes in serum gonadotropin levels after OCP affect outcomes of GnRH-antagonist treated IVF/ICSI cycles

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schmitz, C., Bocca, S., Beydoun, H. et al. Does the degree of hypothalamic-pituitary-ovarian recovery after oral contraceptive pills affect outcomes of IVF/ICSI cycles receiving GnRH-antagonist adjuvant therapy in women over 35 years of age?. J Assist Reprod Genet 29, 877–882 (2012). https://doi.org/10.1007/s10815-012-9812-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10815-012-9812-0

Keywords

Search

Navigation